Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting

References

• The Global Asthma Report [Internet]. 2014. Auckland, New Zealand: The Global Asthma Network. http://www.globalasthmareport.org/resources/Global_Asthma_Report_2014.pdf. Accessed October 1, 2015
   Google Scholar
• Prevention and control of diseases: chronic respiratory disease [Internet]. http://www.paho.org/bra/index2.php?option=com_content&do_pdf =1&id = 581. Accessed October 1, 2015
   Google Scholar
• Costa E, Bregman M, Araujo DV, et al. Asthma and the socio-economic reality in Brazil. W Allergy Organ J 2013;6:20
   PubMedGoogle Scholar
• Sistema de Informações de Mortalidade [Internet]. http://datasus.saude.gov.br/sistemas-e-aplicativos/eventos-v/sim-sistema-de-informacoes-de-mortalidade. Accessed August 13, 2015
   Google Scholar
• Fernandes AG, Souza-Machado C, Coelho RC, et al. Risk factors for death in patients with severe asthma. J Bras Pneumol 2014;40:364-72
   PubMed Web of Science ®Google Scholar
• Peters SP, Ferguson G, Deniz Y, et al. Uncontrolled asthma: A review of the prevalence, disease burden and options for treatment. Respir Med 2006;100:1139-51
   PubMed Web of Science ®Google Scholar
• Global Strategy for Asthma Management and Prevention [Internet]. 2015. Global Initiative for Asthma. http://ginasthma.org/wp-content/uploads/2016/01/GINA_Report_2015_Aug11-1.pdf. Accessed August 30, 2015
   Google Scholar
• Lasmar L, Camargos P, Champs NS, et al. Adherence rate to inhaled corticosteroids and their impact on asthma control. Allergy 2009;64:784-9
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16
   PubMed Web of Science ®Google Scholar
• Sarinho E, Cruz AA. Anti-IgE monoclonal antibody for the treatment of the asthma and other manifestations related to allergic diseases. J Pediatr (Rio J) 2006;82(5Suppl):S127-S32
   Google Scholar
• Tough SC, Hessel PA, Ruff M, et al. Features that distinguish those who die from asthma from community controls with asthma. J Asthma 1998;35:657-65
   PubMed Web of Science ®Google Scholar
• Santos LA, Oliveira MA, Faresin SM, et al. Direct costs of asthma in Brazil: a comparison between controlled and uncontrolled asthmatic patients. Braz J Med Biol Res 2007;40:943-8
   PubMed Web of Science ®Google Scholar
• Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011;66:671-8
   PubMed Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011;154:573-82
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011;364:1005-15
   PubMed Web of Science ®Google Scholar
• Levy AN, Garcia ARAJ, Garcia-Agua Soler N, et al. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. J Asthma 2015;52:205-10
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Canvin J, Peachey G, et al. Healthcare resource utilization in patients receiving omalizumab for allergic asthma in a real-world setting. Biol Ther 2014;4:57?67
   PubMedGoogle Scholar
• Brown R, Turk F, Dale P, et al. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62:149-53
   PubMed Web of Science ®Google Scholar
• Dewilde S, Turk F, Tambour M, et al. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22:1765-76
   PubMed Web of Science ®Google Scholar
• van Nooten F, Stern S, Braunstahl GJ, et al. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ 2013;16:342-8
   PubMedGoogle Scholar
• Braunstahl GJ, Chen CW, Maykut R, et al. The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med 2013;107:1141-51
   PubMed Web of Science ®Google Scholar
• Tsuchiya A. Brazier J. McColl E. Parkin D. Deriving preference-based single indices from non-preference based condition-specific instruments: Converting AQLQ into EQ5D indices [Internet]. 2002. The University of Sheffield. http://eprints.whiterose.ac.uk/10952/. Accessed January 9, 2015
   Google Scholar
• Rubin AS, Souza-Machado A, Andradre-Lima M, et al. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J Asthma 2012;49:288-93
   PubMed Web of Science ®Google Scholar
• Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 2007;16:22-7
   PubMedGoogle Scholar
• SIGTAP (Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e OPM do SUS) [Internet]. http://sigtap.datasus.gov.br/tabela-unificada/app/sec/inicio.jsp. Accessed August 13, 2015
   Google Scholar
• Banco de Preços em Saúde (BPS). Ministério da Saúde. [Internet]. http://aplicacao.saude.gov.br/bps/visao/acessoPublico/acessoPublico.jsf. Accessed August 12, 2015
   Google Scholar
• Norman G, Faria R, Paton F, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess 2013;17:1-342
   PubMed Web of Science ®Google Scholar
• Lowhagen O, Ekstrom L, Holmberg S, et al. Experience of an emergency mobile asthma treatment programme. Resuscitation 1997;35:243-7
   PubMed Web of Science ®Google Scholar
• Cost-effectiveness and strategic planning (WHO-CHOICE) [Internet]. http://www.who.int/choice/costs/CER_levels/en/. Accessed August 28, 2015
   Google Scholar
• Murphy AC, Proeschal A, Brightling CE, et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax 2012;67:751-3
   PubMed Web of Science ®Google Scholar
• Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377-84
   PubMed Web of Science ®Google Scholar
• Chipps BE, Zeiger RS, Dorenbaum A, et al. Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort. Curr Respir Care Rep 2012;1:259-69
   PubMedGoogle Scholar
• Miller MK, Lee JH, Miller DP, et al. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med 2007;101:481-9
   PubMed Web of Science ®Google Scholar
• Alvarez GG, Schulzer M, Jung D, et al. A systematic review of risk factors associated with near-fatal and fatal asthma. Can Respir J 2005;12:265-70
   PubMedGoogle Scholar
• Suzuki C, Carvalho-Netto E, Maia S, et al. Avaliação econômica da adição de omalizumabe ao tratamento de pacientes com asma alérgica grave não controlada sob a perspectiva do Sistema Único de Saúde do Brasil [Economic evaluation of omalizumab add-on therapy in patients with uncontrolled severe allergic asthma from the perspective of Unified Health System in Brazil]. RBM Revista Brasileira de Medicina (Rio de Janeiro) 2015;72:18-26 [Portuguese]
   Google Scholar
• Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma 2012;49:843-8
   PubMed Web of Science ®Google Scholar
• Omalizumab for treating severe persistent allergic asthma NICE technology appraisal guidance [TA278] [Internet]. 2013. https://www.nice.org.uk/guidance/ta278. Accessed April 16, 2014
   Google Scholar
• Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 2010;65:1141-8
   PubMed Web of Science ®Google Scholar
• Wu AC, Paltiel AD, Kuntz KM, et al. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007;120:1146-52
   PubMed Web of Science ®Google Scholar